Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Current Liabilities (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Total Current Liabilities for 11 consecutive years, with $103.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 6.29% to $103.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $103.9 million, a 6.29% decrease, with the full-year FY2025 number at $103.9 million, down 6.29% from a year prior.
  • Total Current Liabilities was $103.9 million for Q4 2025 at Intellia Therapeutics, up from $93.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $131.1 million in Q3 2022 to a low of $60.7 million in Q1 2021.
  • A 5-year average of $105.1 million and a median of $104.5 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 107.75% in 2022, then decreased 29.88% in 2023.
  • Intellia Therapeutics' Total Current Liabilities stood at $125.8 million in 2021, then increased by 0.57% to $126.6 million in 2022, then decreased by 8.97% to $115.2 million in 2023, then dropped by 3.78% to $110.9 million in 2024, then decreased by 6.29% to $103.9 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Total Current Liabilities are $103.9 million (Q4 2025), $93.7 million (Q3 2025), and $95.5 million (Q2 2025).